HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	11/28/2000 4:12:59 PM
From: nigel bates	Read Replies (1) of 1022

Nov. 28 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI - news) and InterMune Pharmaceuticals, Inc. (Nasdaq: ITMN - news) today announced an agreement under which PDL will humanize an InterMune monoclonal antibody targeted to the bacteria Pseudomonas aeruginosa. Pseudomonas aeruginosa is a bacterium that often affects patients using respirators and catheters as well as patients with a number of conditions, including ventilator-associated pneumonia, burns, low white blood cell counts and cystic fibrosis. The target of the monoclonal antibody, PcrV, is a membrane protein on Pseudomonas aeruginosa that facilitates the virulence, or disease-causing ability of these bacteria. The antibody has been shown to be effective in preclinical animal models of infection. PDL will receive an upfront fee and will be entitled to milestone payments upon the achievement of specified objectives, annual maintenance payments and royalties on any product sales. Detailed financial terms were not disclosed. PDL recognizes upfront fees from humanization contracts over the period in which the work is conducted, typically several months....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next